Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Public ClinicalTrials.gov record NCT02037529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study identification
- NCT ID
- NCT02037529
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 201 participants
Conditions and interventions
Conditions
Interventions
- Eribulin Mesylate Drug
- Laboratory Biomarker Analysis Other
- Paclitaxel Drug
- Quality-of-Life Assessment Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2014 (Actual)
- Primary completion
- Feb 11, 2021 (Actual)
- Completion
- Oct 31, 2024 (Estimated)
- Last update posted
- Aug 20, 2024
2014 – 2024
United States locations
- U.S. sites
- 39
- U.S. states
- 22
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Christiana Care Health System-Christiana Hospital | Newark | Delaware | 19718 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Illinois CancerCare-Peoria | Peoria | Illinois | 61615 | — |
| Carle Cancer Center NCI Community Oncology Research Program | Urbana | Illinois | 61801 | — |
| Oncology Associates at Mercy Medical Center | Cedar Rapids | Iowa | 52403 | — |
| Iowa-Wide Oncology Research Coalition NCORP | Des Moines | Iowa | 50309 | — |
| Siouxland Regional Cancer Center | Sioux City | Iowa | 51101 | — |
| Cancer Center of Kansas - Wichita | Wichita | Kansas | 67214 | — |
| Ochsner NCI Community Oncology Research Program | New Orleans | Louisiana | 70121 | — |
| Lafayette Family Cancer Center-EMMC | Brewer | Maine | 04412 | — |
| Cancer Research Consortium of West Michigan NCORP | Grand Rapids | Michigan | 49503 | — |
| Essentia Health NCI Community Oncology Research Program | Duluth | Minnesota | 55805 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud | Minnesota | 56303 | — |
| University of Missouri - Ellis Fischel | Columbia | Missouri | 65212 | — |
| Heartland Regional Medical Center | Saint Joseph | Missouri | 64507 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Heartland Cancer Research CCOP | St Louis | Missouri | 63131 | — |
| Cancer Alliance of Nebraska | Omaha | Nebraska | 68106 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| New Hampshire Oncology Hematology PA-Hooksett | Hooksett | New Hampshire | 03106 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse | New York | 13057 | — |
| Mission Hospital-Saint Joseph Campus | Asheville | North Carolina | 28801 | — |
| Cone Health Cancer Center at Alamance Regional | Burlington | North Carolina | 27215 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina | 27534 | — |
| FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst | North Carolina | 28374 | — |
| Novant Health Forsyth Medical Center | Winston-Salem | North Carolina | 27103 | — |
| Cancer Centers of Southwest Oklahoma Research | Lawton | Oklahoma | 73505 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57701 | — |
| Edwards Comprehensive Cancer Center | Huntington | West Virginia | 25701 | — |
| Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02037529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2024 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02037529 live on ClinicalTrials.gov.